Recombinant IL2RA (Daclizumab Biosimilar) 抗体
-
- 抗原 See all IL2RA (Daclizumab Biosimilar) products
- IL2RA (Daclizumab Biosimilar)
- 抗体类型
- Recombinant Antibody
-
适用
- 人
-
宿主
-
Mammalian Cells
- Expression System
- Mammalian cells
-
克隆类型
- 单克隆
-
标记
- This IL2RA (Daclizumab Biosimilar) antibody is un-conjugated
-
应用范围
- ELISA
- 原理
- Daclizumab Biosimilar - Anti-IL2RA mAb
- 产品特性
- Antibody Type: IgG1-kappa
- 纯化方法
- Recombinant antibody expressed in mammalien cells and purified.
- 质量等级
- Research Grade
- 亚型
- IgG1 kappa
-
-
- 限制
- 仅限研究用
-
- 缓冲液
- PBS pH 7.5
- 储存条件
- -80 °C
- 储存方法
- store at -80°C
-
- 抗原
- IL2RA (Daclizumab Biosimilar)
- Abstract
- IL2RA (Daclizumab Biosimilar) 产品
- 别名
- CD25 antibody, IDDM10 antibody, IL2R antibody, TCGFR antibody, interleukin 2 receptor subunit alpha antibody, IL2RA antibody
- 物质类
- Biosimilar
- 背景
-
BIIB019,DAC HYP
Daclizumab is a humanized IgG1 monoclonal antibody that binds to human interleukin 2 receptor (anti-Tac or anti-CD25)and composed of human >90%) and murine (10%) antibody sequences. The human sequence is derived from the constant domain of human IgG1 and the variable framework region of Eu myeloma antibody. The murine part was taken from the complementarity-determining regions of a murine anti-Tac antibody. Daclizumab has been used for preventing acute organ rejection in de novo allogeneic kidney transplantation when used simultaneously with immunosuppressive regimens such as cyclosporine and corticosteroid and in the treatment of adult patients with relapsing multiple sclerosis. These trademarks were Zenapax and Zimbryta, respectively. - CAS-编号
- 152923-56-3
-